Sprue-Like Small Intestinal Diseases 2024

Hugh James Freeman^1,

¹Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada

Cite this paper:
Hugh James Freeman. Sprue-Like Small Intestinal Diseases 2024. International Journal of Celiac Disease. 2024; 12(1):12-15. doi: 10.12691/ijcd-12-1-2

Abstract

Celiac disease (also termed gluten-sensitive enteropathy) is a gluten-dependent immune-mediated disorder of the small intestinal mucosa. This disease occurs in genetically-predisposed individuals and serological studies in different populations estimate that about 1% of screen-positive individuals may eventually be diagnosed with celiac disease. However, a number of other disorders, labeled sprue-like intestinal disease, may also cause the pathological appearances of celiac disease, such as mucosal injury from oats or other proteins (eg., soy), along with a wide array of infections, including protozoans, viral, bacterial and parasitic agents. Some nutrient or vitamin deficiencies including zinc, folic acid and vitamin B12 along with an array of immune deficiency syndromes may cause a sprue-like enteropathy with the histopathological features of untreated celiac disease. None of these respond to a gluten-free diet. Instead, other forms of therapy may lead to resolution. Medications including pharmacological (eg., olmesartan) and biological agents (eg., checkpoint inhibitors) may cause sprue-like small intestinal disease. Ceasing use of the medication may lead to resolution of mucosal injury

Keywords:
sprue-like intestinal disease celiac disease collagenous sprue gluten-free diet medication-induced small bowel disease

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Freeman HJ, Chopra A, Clandinin MT, Thomson AB. Recent advances in celiac disease. World J Gastroenterol 2011; 17: 2259-2272.
[2]	Gujral N, Freeman HJ, Thomson AB. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol 2012; 18: 6036-6059.
[3]	Freeman HJ. Pearls and pitfalls in the diagnosis of adult celiac disease. Can J Gastroenterol 2008; 22: 273-280.
[4]	MacDonald WC, Brandborg LL, Flick AL, Trier JS, Rubin CE. Studies of celiac sprue. IV. The response of the whole length of the small intestine to a gluten-free diet. Gastroenterology 1964; 47: 573-589.
[5]	Freeman HJ. Mucosal recovery and mucosal healing in biopsy-defined adult celiac disease. Inter J Celiac Dis 2017; 5: 14-18.
[6]	Freeman HJ. Dietary compliance in adult celiac disease. World J Gastroenterol 2017; 23: 2635-2639.
[7]	Makovicky P, Makovicky P, Lupan I, Samasca G, Sur G, Freeman HJ. Gluten-free products for patients with celiac disease should not contain trace levels. Adv Nutr 2017; 8: 409-411.
[8]	Silvester JA, Comino I, Kelly CP, Sousa C, Duerksen DR. Most patients with celiac disease on gluten-free diets consume measurable amounts of gluten. Gastroenterology 2020; 158: 1497-1499.
[9]	Schuffler MD, Chaffee RG. Small intestinal biopsy in a patient with Crohn’s disease of the duodenum. The spectrum of abnormal findings in the absence of granulomas. Gastroenterology 1979; 76: 1009-1014.
[10]	Annese V, Caruso N, Bisceglia M, Lombardi G, Glemente R, Modola G, Tardio B, Villani MR, Andriulli A. Fatal ulcerative panenteritis following colectomy in a patient with ulcerative colitis. Dig Dis Sci 1999; 44: 1189-1195.
[11]	Rosenfeld GA, Freeman HJ, Brown M, Steinbrecher UP. Severe and extensive enteritis following colectomy for ulcerative colitis. Can J Gastroenterol 2012; 2: 866-867.
[12]	Freeman HJ. Sprue-like intestinal disease following Crohn’s disease. Inter J Celiac Dis 2019; 7: 92-92.
[13]	Freeman HJ. Sprue-like intestinal disease following colectomy for inflammatory bowel disease. SL Gastroenterology 2020; 3: 131 (01-06).
[14]	Rubin CE, Eidelman S, Weinstein WM. Sprue by any other name. Gastroenterology, 1970; 58: 409-413.
[15]	Cellier C, Patey N, Mauvieux L, Jabri B, Delabesse E, Cervoni JP, Burtin ML, Guy-Grand D, Bouhnik Y, Modigliani R, Barbier JP, Macintyre E, Brousse N, Cerf-Bensussan N. Abnormal intestinal intraepithelial lymphocytes refractory sprue. Gastroenterology 1998; 114; 471-481.
[16]	Malamut G, Afchain P, Verkarre V, Lecomte T, Amiot A, Damotte D, Bouhnik Y, Colombel JF, Delchier JC, Allez M, Cosnes J, Lavergne-Slove A, Meresse B, Trinquart L, Macintyre E, Radford-Weiss I, Hermine O, Brousse N, Cerf-Bensussan N, Cellier C. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology, 2009; 136: 81-90.
[17]	Freeman, H.J. Sprue-like intestinal disease complicated by inclusion body myositis. Inter J Celiac Dis 2019; 7: 53-55.
[18]	Colizzo FP, Shroff SG, High FA, Chen Y-B, Bermettler S. A 33-year-old man with chronic diarrhea and autoimmune enteropathy. N Engl J Med 387: 1124-1134.
[19]	Freeman HJ, Nimmo M. Isoretinoin-associated celiac disease. Inter J Celiac Dis 2018; 6: 89-92.
[20]	Robinson JW. Intestinal malabsorption in the experimental animal. Gut, 1972; 13: 938-945.
[21]	Wilson FA Hoyumpa AM Jr. Ethanol and small intestinal transport. Gastroenterology, 1979; 76: 388-403.
[22]	Trier JS. Morphologic alterations induced by methotrexate in the mucosa of the human proximal intestine. I. Serial observations by light microscopy. Gastroenterology, 1962; 42: 295-305.
[23]	Longstreth GF, Newcomer AD. Drug-induced malabsorption. Mayo Clinic Proc 1975; 50: 284-293.
[24]	Jacobson ED, Prior JT Faloon WW. Malabsorptive syndrome induced by neomycin: morphologic alterations in the jejunal mucosa. J Lab Clin Med 1960; 56: 245-250.
[25]	Race TF, Paes IC, Faloon WW. Intestinal malabsorption induced by oral colchicine. Comparison with neomycin and cathartic agents. Am J Med Sci 1970; 259: 32-41.
[26]	Wright N, Watson A, Morley A, Appleton D, Marks J Douglas A. The cell cycle time in flat (avilllous) mucosa of the human small intestine. Gut 1973; 14: 603-606.
[27]	Freeman HJ. Sulindac associated small bowel lesion. J Clin Gastroenterol 1986; 8: 569-571.
[28]	Ziegler TR, Fernandez-Estivariz C, Gu LH, Fried MW, Leader, L.M. Severe villous atrophy and chronic malabsorption induced by azathioprine. Gastroenterology 2003; 124: 1950-1957.
[29]	Freeman HJ. Olmesartan enteropathy. Inter J Celiac Dis, 2016; 4: 24-26.
[30]	Freeman HJ. Olmesartan-induced collagenous sprue. Inter J Celiac Dis, 2020; 8: 32-34.
[31]	Gentile M, D’Souza A, Fujii LL, Wu TT, Murray JA. Association between ipilimumab and celiac disease. Mayo Clin Proc 2013; 88: 414-417.
[32]	Freeman HJ. Sprue-like intestinal disease induced by checkpoint inhibitor immunotherapy. Inter J Celiac Dis, 2020; 8: 28-31.
[33]	Duval L, Habes S, Chatellier T, Guerzider P, Bossard C, Mesliah C, Archambeaud I, Touchefeu Y, Matysiak-Budnik T. (2019). Nivolumab induced celiac-like enteropathy in patient with metastatic renal cell carcinoma. Clin Case Rep 2019; 7: 1689-1693.
[34]	Facchinetti F, Gnetti L, Caruana P, Fornaroli F, de-Angelis GL, Sabato M, Ferri L, Cosenza A, Bordi P, Disco M. Widespread nivolumab-induced enteropathy in long responder non-small cell lung cancer patient. Clin Lung Cancer, 2018; 19: e591-e596,
[35]	Arnouk J, Matthew D, Nulton E, Rachakonda V. A celiac disease phenotype after checkpoint inhibitor exposure: an example of immune dysregulation after immunotherapy. ACG Case Rep J 2019; 6: e00158.
[36]	Alsaadi D, Shah NJ, Charabaty A, Atkins, M.B. A case of checkpoint inhibitor-induced celiac disease. J Immunother Cancer 2019; 7: 203.